June 26-28, 2018

Frankfurt, Germany

Pre-Conference Workshop Day
Tuesday 26th June, 2018

09.00 - 12.00
Identify the Next Generation of Armed Therapeutics in Combination
Workshop Leader: John Bell, Professor of Medicine, Ottawa Health Research Institute

As the hottest area of oncolytic immunotherapies is the arming of viruses in line with combinational therapy approaches, this workshop will provide the opportunity to engage in an in-depth discussion exploring the  future of armed therapeutics. Join this workshop to identify the ideal arming payloads and combination strategies to improve your immuno-oncolytic pipeline.

Attend this session to discuss:

  • What characteristics should be engineered or selected for, to create the optimal oncolytic virus?
  • What are the best “cis and/or trans” combination approaches to enhance both viral oncolysis and antitumor immune responses?
  • Classes of transgenes that could be encoded into an OV backbone?
  • What are the challenges and advantages to encoding multiple payloads within a single oncolytic virus therapeutic?

John Bell, Professor of Medicine, Ottawa Health Research Institute

John Bell is an international leader in the development of oncolytic viruses that selectively infect and kill cancer cells, while leaving healthy tissues unharmed. His research lab focuses on the discovery/design of oncolytic viruses, their manufacture and clinical translation.  He is a Scientific Co-founder of Turnstone Biologics which is clinically testing rhabdovirus based oncolytic virus vaccine products and a novel vaccinia virus platform encoding multiple therapeutic transgenes. John is a Senior Scientist at the Ottawa Hospital Research Institute and the Scientific Director of a Canadian National Network (BioCanRx) aimed at translating Anti-Cancer Biotherapeutics from the laboratory into the Clinic.

13.00 - 16.00
Novel Forms of Delivery for Oncolytic Immunotherapies
Workshop Leader: Talia Biran, VP, Clinical Development and Medical Affairs, , Oncolys USA

One of the greatest challenges in this therapeutic area is the use of an un-invasive delivery system that is able to travel intravenously to the tumor site and overcome the immune system response. This workshop explores the hurdles using intratumoral delivery compared to a systemic approach of intravenous delivery.

Attend this session to discuss:

  • Novel forms of delivery devices for intravenousdelivery
  • Explore the hurdles limiting systemic delivery
  • Identify the benefits and handicaps of intratumoraldelivery

Talia Biran, VP, Clinical Development and Medical Affairs, , Oncolys USA

Talia Biran joined Oncolys USA in 2017, with over 25 years of experience in Medical affairs. Having worked at Janssen, Merck and Novartis, she contributed to the development and launch of Abiraterone Acetate (Zytiga ®, prostate cancer), Vorinostat (Zolinza®, CTCL), Letrozole (Femara®, breast cancer) and Octreotide (Sandostatin LAR®, neuroendocrine tumors (NETs) and acromegaly)

Prior to Oncolys, Talia played a pivotal role at Lexicon Pharmaceuticals as Executive Director, where she established the US medical affairs infrastructure for Oncology and Diabetes programs and led the development and launch of Lexicon’s first drug candidate, Telotristat Ethyl ( Xermelo, ® Carcinoid Syndrome Diarrhea) (Licensed Ex-US to Ipsen Inc)

Talia holds a Master of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, in Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorigenesis.